FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)		9 Months Ended	12 Months Ended
Oct. 06, 2023	Mar. 31, 2025	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Available for sale securities aggregate cost		$ 2,651,000	$ 3,964,000
Realized gain on marketable equity securities		595,000
Investments included net unrealized gains (losses)		2,900,000	1,800,000
Gross unrealized gains		3,400,000	2,100,000
Gross unrealized losses		493,000	261,000
Marketable equity securities		$ 797,000	$ 987,000
Warrant description	On October 6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc. (“Monogram”), we exercised a warrant to purchase common stock of Monogram (the “Monogram Warrant”) in full in cash totaling $1,250,000 and received 1,828,551 shares of Monogram common stock (NasdaqCM: MGRM). The fair value of the Monogram common stock is reflected in marketable equity securities – short term in the tables above.

Available for sale securities aggregate cost

$ 2,651,000

$ 3,964,000

Investments included net unrealized gains (losses)

2,900,000

1,800,000

Gross unrealized losses

493,000

261,000

Warrant description

On October 6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc. (“Monogram”), we exercised a warrant to purchase common stock of Monogram (the “Monogram Warrant”) in full in cash totaling $1,250,000 and received 1,828,551 shares of Monogram common stock (NasdaqCM: MGRM). The fair value of the Monogram common stock is reflected in marketable equity securities – short term in the tables above.